15 results about "Cell-mediated cytotoxicity" patented technology

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and / or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and / or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and / or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

Compositions and methods are described for a treatment of enduring viral infection in general, and long COVID in particular. The composition comprises T cells, antigen presenting cells (APC), and optionally NK cells derived from the whole blood of a patient. The APC are genetically engineered to comprise nucleic acids encoding antigenic peptide sequences for MHC-complexed cell surface expression, wherein further exposure to an IL-15 agonist and patient T cells yields activation and expansion of virally-educated T cells for re-administration to the patient, whereby cells harboring the virus are targeted for T-cell mediated cytotoxicity

The present invention relates to IgG1 Fc variants which do not elicit antibody effector functions, such as CDC, ADCP and ADCC. In particular, the present invention relates to IgG1 Fc variant polypeptides which comprise the mutations L234A, L235A, A327G, P329A, A330S, and P331S, according to EU numbering, molecules comprising such IgG1 Fc variant polypeptides and uses of such molecules to reduce antibody effector function.

Methods for treating T cells with venetoc to enhance T cell-mediated cytotoxicity and / or T cell-mediated antitumor activity are described. Enhanced T cell populations and their related methods and uses in cancer treatment are also described.

The invention discloses a bispecific fully humanized single-domain antibody targeting a novel coronavirus and CD16a and an application of the bispecific fully humanized single-domain antibody. The antibody comprises a single-domain antibody n3130v targeting a novel coronavirus and a single-domain antibody n118 targeting a human CD16a, the amino acid sequence of the n3130v is as shown in SEQ ID NO: 1, and the amino acid sequence of the n118 is as shown in SEQ ID NO: 2. The antibody disclosed by the invention has the capabilities of broad-spectrum recognition and neutralization of novel coronavirus, can be efficiently combined with a CD16a target spot, and is used for mediating antibody-dependent cell-mediated cytotoxic action (ADCC). The bispecific antibody can be used for novel coronavirus related research and treatment of diseases caused by novel coronavirus infection.

Compositions and methods for treating general persistent viral infections, particularly long COVID, are described. The compositions comprise T cells, antigen presenting cells (APCs), and optionally NK cells derived from a patient's whole blood. The APCs are genetically engineered to comprise nucleic acids encoding antigenic peptide sequences for MHC-complexed cell surface expression, where further exposure to an IL-15 agonist and patient T cells can produce activation and expansion of virus-educated T cells for readministration to the patient, thereby targeting cells harboring the virus to T cell-mediated cytotoxicity.

This disclosure pertains to a nucleic acid encoding a fusion protein that specifically targets CD300A. It also provides pluralities of nucleic acids that further comprise a chimeric receptor-encoding nucleic acid, such as a nucleic acid encoding a NK-targeting CAR. Vectors, compositions, engineered cells, and populations of cells containing such nucleic acids are also provided herein. Uses of these fusion proteins, nucleic acids, vectors, engineered cells, or populations of engineered cells in promoting resistance to NK cell-mediated cytotoxicity in an allogeneic setting, preventing or treating transplant rejection, and preventing or treating diseases, such as cancers or autoimmune diseases, are also provided herein.

A novel fusion protein to overcome the current difficulties related to application of monoclonal antibodies in disease treatment and in other fields, particularly those requiring ADCC, e.g. for depletion of tumor cells, virally-infected cells, or immune-modulating cells, etc. One example of the fusion protein is an extracellular domain of a high-affinity variant of human CD 16 A fused to an anti-CD3 antibody or its antigen-binding fragment thereof that specifically binds to an epitope on human CD3 or a fragment thereof.

Compositions and methods are described for a treatment of enduring viral infection in general, and long COVID in particular. The composition comprises T cells, antigen presenting cells (APC), and optionally NK cells derived from the whole blood of a patient. The APC are genetically engineered to comprise nucleic acids encoding antigenic peptide sequences for MHC-complexed cell surface expression, wherein further exposure to an IL-15 agonist and patient T cells yields activation and expansion of virally-educated T cells for re-administration to the patient, whereby cells harboring the virus are targeted for T-cell mediated cytotoxicity.

Described herein are bispecific antibodies simultaneously targeting both CHI3L1 and the immune checkpoint molecule PD-1. These antibodies manifest enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. Methods of treating a cancer by administering the bispecific antibodies described herein are also provided.

This invention provides a pharmaceutical composition for treating cancer through effective immunotherapy against immune checkpoint inhibitor molecules. [Solution] A bispecific antibody is provided that detects and neutralizes CHI3L1 and PD-1, comprising an antigen-binding moiety of an anti-human programmed death receptor 1 (PD-1) antibody and an antigen-binding moiety of an anti-human chitinase 3-like-1 (CHI3L1) antibody.

The invention discloses a bispecific fully-humanized single-domain antibody targeting a new coronavirus and CD16a and an application of the bispecific fully-humanized single-domain antibody. The antibody comprises a single-domain antibody n3130v targeting a new coronavirus and a single-domain antibody n118 targeting a human CD16a, the amino acid sequence of the n3130v is as shown in SEQ ID NO: 1, and the amino acid sequence of the n118 is as shown in SEQ ID NO: 2. The antibody disclosed by the invention has the capabilities of broad-spectrum recognition and neutralization of novel coronavirus, can be efficiently combined with a CD16a target spot, and is used for mediating antibody-dependent cell-mediated cytotoxic action (ADCC). The bispecific antibody can be used for novel coronavirus related research and treatment of diseases caused by novel coronavirus infection.

The invention relates to application of corilagin in preparation of a staphylococcus aureus inhibitor. Experiments prove that corilagin is directly combined with staphylococcus aureus cell wall hydrolase, so that bacterial proliferation is slowed down, and biofilm formation is reduced; the hemolytic activity of the alpha-hemolysin protein and the bacterial culture supernatant can be reduced through two ways of directly inhibiting the staphylococcus aureus alpha-hemolysin and inhibiting the secretion of the staphylococcus aureus alpha-hemolysin to the culture medium supernatant; corilagin has no cytotoxic effect, and can significantly inhibit human pulmonary epithelial cell-mediated cytotoxicity and adhesion effect of staphylococcus aureus; by constructing a staphylococcus aureus infected mouse pneumonia model, it is found that corilagin remarkably improves the survival rate of infected mice, colonization of staphylococcus aureus in mice lungs is reduced, and edema and inflammatory response of the mice lungs are relieved. The results show that corilagin has a good application prospect in the aspect of resisting staphylococcus aureus infection.

To provide more effective immunotherapy against individual immune checkpoint inhibitor molecules such as PD-1.SOLUTION: The present invention provides a humanized bispecific antibody that simultaneously detects and neutralizes both CHI3L1 and the immune checkpoint inhibitor PD-1, wherein these antibodies exhibit enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. A pharmaceutical composition comprising the bispecific antibody, and a therapeutic agent for cancer comprising the bispecific antibody, are also provided.SELECTED DRAWING: None